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Abstract The present study underlines the importance of
lovastatin, an inhibitor of 3-hydroxy-3-methyl-glutaryl-coen-
zyme A (HMG-CoA) reductase, and the sodium salt of
phenylacetic acid (NaPA), an inhibitor of mevalonate pyrophos-
phate decarboxylase, in normalizing the pathognomonic accu-
mulation of saturated very long chain fatty acids (VLCFA) in
cultured skin fibroblasts of X-adrenoleukodystrophy (X-ALD) in
which the ALD gene is either mutated or deleted. Lovastatin or
NaPA alone or in combination stimulated the L-oxidation of
lignoceric acid (C24:0) and normalized the elevated levels of
VLCFA in skin fibroblasts of X-ALD. Ability of lovastatin and
NaPA to normalize the pathognomonic accumulation of VLCFA
in skin fibroblasts of X-ALD may identify these drugs as possible
therapeutics for X-ALD.
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1. Introduction
X-linked adrenoleukodystrophy (X-ALD), an inherited per-
oxisomal disorder, is characterized by progressive demyelina-
tion and adrenal insu⁄ciency. It is the most common perox-
isomal disorder a¡ecting between 1/15 000 and 1/20 000 boys
with the manifestation of di¡erent degrees of neurological
disability. Although X-ALD presents as various clinical phe-
notypes, including childhood X-ALD, adrenomyeloneuro-
pathy (AMN), and Addison’s disease, all forms of X-ALD
are associated with the pathognomonic accumulation of satu-
rated very long chain fatty acids (VLCFA) as a constituent of
cholesterol esters, phospholipids and gangliosides [1,2]. Due
to the presence of similar concentration of VLCFA in plasma
and as well as in ¢broblasts of X-ALD, ¢broblasts are gen-
erally used for both prenatal and postnatal diagnosis of the
disease [1,2].
A number of laboratories, including ours, showed that L-
oxidation of VLCFA is a peroxisomal function [3^7]. The
de¢cient activity of lignoceroyl-CoA ligase as compared to
the normal oxidation of lignoceroyl-CoA in puri¢ed peroxi-
somes isolated from ¢broblasts of X-ALD suggested that the
abnormality in the oxidation of VLCFA may be due to de¢-
cient activity of lignoceroyl-CoA ligase required for the acti-
vation of lignoceric acid to lignoceroyl-CoA [4,6]. While these
metabolic studies indicated lignoceroyl-CoA ligase gene as a
X-ALD gene, positional cloning studies led to the identi¢ca-
tion of a gene that encodes a protein (ALDP), with signi¢cant
homology with the ATP-binding cassette (ABC) of the super-
family of transporters [8]. The normalization of fatty acids in
X-ALD cells following transfection of the X-ALD gene [9]
supports a role for ALDP in fatty acid metabolism; however,
the precise function of ALDP in the metabolism of VLCFA is
not known at present.
Similar to other genetic diseases a¡ecting the central nerv-
ous system, gene therapy in X-ALD does not seem to be a
real option in the near future and in the absence of such a
treatment a number of therapeutic applications have been
investigated [1,10]. Adrenal insu⁄ciency associated with X-
ALD responds readily to steroid replacement therapy; how-
ever, there is as yet no proven remedy for the neurological
disability [10]. Two forms of treatment are currently under
investigation. The dietary therapy with ‘Lorenzo’s oil’ does
normalize the plasma levels of VLCFA, but it does not
seem to improve the clinical status of the X-ALD patients
[10^12]. Bone marrow transplantation also appears to be of
only limited value because of the complexity of the protocol
and the insigni¢cant improvement in the clinical status of the
patient [10].
The studies described in this article demonstrate that lova-
statin and sodium phenylacetate (NaPA), inhibitors of the
mevalonate pathway, normalize the levels of VLCFA in skin
¢broblasts of X-ALD by increasing the peroxisomal activity
for L-oxidation of VLCFA. In light of the fact that these
compounds also inhibit the induction of proin£ammatory cy-
tokines and nitric oxide synthase in astrocytes and microglia
[13], we propose that these drugs may have therapeutic po-
tential in correction of the metabolic defect and inhibition of
the neuroin£ammatory disease process in X-ALD.
2. Materials and methods
2.1. Reagents
DMEM, bovine calf serum and Hanks’ bu¡ered salt solution
(HBSS) were from Gibco. [1-14C]Lignoceric acid was synthesized by
treatment of n-tricosanoyl bromide with K14CN as described previ-
ously [14].
2.2. Enzyme assay for L-oxidation of lignoceric acid
The enzyme activity of [1-14C]lignoceric acid L-oxidation to acetate
was measured in intact cells suspended in HBSS. Brie£y, the reaction
mixture in 0.25 ml of HBSS contained 50^60 g of protein and 6 WM
[1-14C]lignoceric acid. Fatty acids were solubilized with K-cyclodextrin
and L-oxidation of [1-14C]lignoceric acid was carried out as described
previously [3,6].
2.3. Measurement of VLCFA in ¢broblasts
Fatty acid methyl ester (FAME) was prepared as described previ-
ously by Lepage and Roy [15] with modi¢cations. Fibroblast cells,
suspended in HBSS, were disrupted by sonication to form a homoge-
neous solution. An aliquot (200 Wl) of this solution was transferred to
a glass tube and 5 Wg heptacosanoic (27:0) acid was added as internal
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standard and lipids were extracted by Folch partition. Fatty acids
were transesteri¢ed with acetyl chloride (200 Wl) in the presence of
methanol and benzene (4:1) for 2 h at 100‡C. The solution was cooled
down to room temperature followed by addition of 5 ml 6% potas-
sium carbonate solution at ice-cooled temperature. Isolation and pu-
ri¢cation of FAME were carried out as detailed by Dacremont et al.
[16]. Puri¢ed FAME, suspended in chloroform, was analyzed by gas
chromatograph GC-15A attached with chromatopac C-R3A integra-
tor from Shimadzu Corporation.
2.4. Preparation of post-nuclear membrane and Western blot analysis
The membranes were prepared as described previously [17]. Brie£y,
the post-nuclear fraction was diluted with an ice-cold solution of 0.1 M
sodium carbonate, 30 mM iodoacetamide, pH 11.5. After 30 min of
incubation at 4‡C, the membranes were sedimented by ultracentrifu-
gation. The sedimented membranes were electrophoresed in 7.5% so-
dium dodecylsulfate-polyacrylamide gel, transferred to PVDF mem-
branes and immunoblotted with antibodies against ALDP as
described [17].
2.5. RNA isolation and Northern blot analysis
Cultured skin ¢broblasts were taken out from culture £asks directly
by adding Ultraspec-II RNA reagent (Biotecx) and total RNA was
isolated according to the manufacturer’s protocol. 20 Wg of RNA
from each sample was electrophoretically resolved on 1.2% denaturing
formaldehyde-agarose gel, transferred to nylon membrane, and cross-
linked using UV Stratalinker (Stratagene, USA). Full length ALDP
cDNA was kindly provided by Dr. Patrick Aubourg, INSERM, Hos-
pital Saint-Vincent-de-Paul, Paris, France. 32P-labeled cDNA probes
were prepared according to the instructions provided with Ready-To-
Go DNA labeling kit (Pharmacia Biotech). Northern blot analysis
was performed essentially as described for Express Hyb Hybridization
solution (Clontech) at 68‡C. GAPDH cDNA probe was used as
standard for comparing hybridization signals.
3. Results
3.1. Inhibitors of mevalonate pathway stimulate the L-oxidation
of lignoceric acid in X-ALD ¢broblasts
First, we studied the e¡ect of mevalonate inhibitors (lova-
statin, mevastatin and NaPA) on the L-oxidation of lignoceric
acid in control human skin ¢broblasts. It is apparent from
Table 1 that lovastatin, mevastatin and NaPA stimulated
the L-oxidation of lignoceric acid in control human skin ¢-
broblasts. Since the L-oxidation of lignoceric acid is impaired
in X-ALD patients, we studied the e¡ect of these compounds
on lignoceric acid L-oxidation in cultured skin ¢broblasts of
X-ALD. Similar to control ¢broblasts, these compounds also
stimulated lignoceric acid L-oxidation in X-ALD ¢broblasts
(Fig. 1). Both lovastatin (Fig. 1A) and NaPA (Fig. 1B) stimu-
lated lignoceric acid L-oxidation in X-ALD ¢broblasts in a
dose-dependent manner. The highest dose of lovastatin found
to stimulate lignoceric acid L-oxidation (by 70%) was 5 WM
whereas the highest dose of NaPA found to stimulate ligno-
ceric acid L-oxidation (by 40%) was 5 mM. However, a great-
er degree of stimulation (more than two-fold) was observed by
a combination of lovastatin and NaPA even at a dose lower
than the one used individually (Fig. 1B). Higher doses of
lovastatin (10^20 WM) or NaPA (10^20 mM) were cytotoxic
to the X-ALD ¢broblasts and did not result in further signi¢-
cant stimulation (data not shown). In the cell fatty acids are
oxidized by mitochondrial and peroxisomal L-oxidation en-
zyme systems. We examined the e¡ect of etomoxir, an inhib-
itor of mitochondrial L-oxidation, on the L-oxidation of fatty
acids [18]. Etomoxir had no e¡ect on lovastatin- or NaPA-
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Table 1
Lovastatin and NaPA stimulate the L-oxidation of lignoceric acid in
control human skin ¢broblasts
Treatment Lignoceric acid L-oxidation
(pmol/h/mg protein)
Control 570.2 þ 52.3
Lovastatin (5 WM) 945.7 þ 105.6
Mevastatin (5 WM) 889.6 þ 78.4
NaPA (5 mM) 826.2 þ 87.2
Cells were treated for 72 h in serum-containing DMEM with the listed
reagents; L-oxidation of lignoceric acid was measured as described in
Section 2. Medium was replaced after every 24 h with the addition of
fresh reagents. Data are mean þ S.D. of three di¡erent experiments.
Fig. 1. Lovastatin and NaPA stimulate the L-oxidation of lignoceric
acid in cultured skin ¢broblasts of X-ALD in a dose-dependent
manner. Cells were incubated in serum-containing DMEM with dif-
ferent concentrations of lovastatin (A) or NaPA in the presence or
absence of 2 WM lovastatin (B). After every 24 h, medium was re-
placed with the addition of fresh reagents. Lignoceric acid L-oxida-
tion was measured after 72 h in cell suspension as mentioned in
Section 2. Values are mean þ S.D. of three di¡erent experiments.
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mediated stimulation of lignoceric acid L-oxidation (data not
shown) suggesting that the observed stimulation of lignoceric
acid L-oxidation was a peroxisomal function.
3.2. Modulation of cellular content of VLCFA in X-ALD
¢broblasts by lovastatin and NaPA
Since mevalonate inhibitors increased L-oxidation of ligno-
ceric acid in control as well as X-ALD ¢broblasts, we exam-
ined the e¡ect of these compounds on the in situ levels of
VLCFA in X-ALD ¢broblasts. Treatment of X-ALD ¢bro-
blasts with 5 WM of lovastatin for di¡erent time periods (days)
resulted in a time-dependent decrease in the ratios of C26:0/
C22:0 and C24:0/C22:0 as shown in Fig. 2. Within 12^15 days of
treatment, the ratios of C26:0/C22:0 and C24:0/C22:0 in X-ALD
¢broblasts decreased to the normal level. Similar to lovastatin,
NaPA also lowered the ratios of C26:0/C22:0 and C24:0/C22:0 in
X-ALD ¢broblasts almost to the normal level after 15 days of
treatment. However, consistent with the higher degree of stim-
ulation of lignoceric acid L-oxidation by a combination of
lovastatin and NaPA, the same combination lowered the ra-
tios of C26:0/C22:0 and C24:0/C22:0 to normal levels within 7
days (Fig. 2). This decrease in the ratios of C26:0/C22:0 and
C24:0/C22:0 was also associated with a decrease in the absolute
amounts of C24:0 and C26:0 whereas no signi¢cant change was
observed in the levels of C22:0 (behenoic acid) (data not
shown).
3.3. Normalization of the levels of VLCFA by lovastatin or
NaPA in di¡erent X-ALD cells with or without deletion
of the X-ALD gene
Although the precise function of ALDP, X-ALD gene
product, in the metabolism of VLCFA is not known at the
present time, however, accumulation of VLCFA in X-ALD
cells with loss or mutations in ALDP and their normalization
following transfection of cDNA for ALDP indicate a role of
ALDP in the metabolism of VLCFA [9]. Therefore, we next
attempted to examine whether lovastatin or NaPA were able
to lower the levels of VLCFA in X-ALD ¢broblast cell lines
with mutation or deletion of the X-ALD gene. The status of
ALDP mRNA or protein (Fig. 3) and the rate of L-oxidation
of lignoceric acid (Table 2) in di¡erent X-ALD ¢broblasts
indicates that ALDS2, ALDS3 and ALDS4 are X-ALD skin
¢broblasts with mutation of the X-ALD gene, whereas
ALDS5 and ALDS6 are X-ALD skin ¢broblasts with deletion
of the X-ALD gene. It is apparent from Table 2 that the
treatment of X-ALD ¢broblasts with lovastatin or NaPA or
a combination of these stimulated the L-oxidation of lignocer-
ic acid (55^80%) and normalized the ratios of C26:0/C22:0 and
C24:0/C22:0 suggesting that these drugs are capable of lowering
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Fig. 2. Time-dependent e¡ect of lovastatin and NaPA on the ratios
of VLCFA (C26:0/C22:0 and C24:0/C22:0) in cultured skin ¢broblasts
of X-ALD. Cells were incubated in serum-containing DMEM with
5 WM lovastatin, 5 mM NaPA or the combination of 2 WM lovasta-
tin and 2 mM NaPA for di¡erent days, and the ratios of C26:0/C22:0
(A) and C24:0/C22:0 (B) were measured as described in Section 2.
Values are mean of two di¡erent experiments.
Fig. 3. Expression of ALDP mRNA and protein in di¡erent skin ¢-
broblasts of X-ALD. Western blot analysis (A) of post-nuclear
membrane fraction with antibodies against ALDP and Northern
blot analysis for ALDP mRNA (B) were carried out as described in
Section 2. ALDS2, ALDS3 and ALDS4 are X-ALD skin ¢broblasts
with mutation of the X-ALD gene, whereas ALDS5 and ALDS6
are X-ALD skin ¢broblasts with deletion of the X-ALD gene.
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the level of VLCFA in X-ALD ¢broblasts to the normal lev-
els, irrespective of mutation or deletion of the X-ALD gene,
the candidate gene for X-ALD.
4. Discussion
In the current work we provide evidence for the possible
therapeutic intervention against pathognomonic accumulation
of VLCFA in X-ALD. Despite mutation or deletion of the X-
ALD gene, lovastatin and NaPA lowered the cellular content
of VLCFA to normal levels in di¡erent skin ¢broblasts of X-
ALD. The detailed mechanism leading to the decrease in the
accumulation of VLCFA in X-ALD ¢broblasts is not known,
but is likely through the stimulation of peroxisomal L-oxida-
tion.
The pathogenetic mechanisms of X-ALD are poorly under-
stood. At present it is not known that how the accumulation
of VLCFA as a result of an inherited defect makes the myelin
sheath unstable and causes demyelination. Recent documen-
tation of the presence of immunoreactive tumor necrosis fac-
tor K (TNF-K) and interleukin 1L (IL-1L) in astrocytes and
microglia of X-ALD brain has suggested the involvement of
these cytokines in immunopathology of X-ALD and aligned
X-ALD with multiple sclerosis (MS), the most common im-
mune-mediated demyelinating disease of the CNS in man [19^
21]. In spite of a signi¢cant progress on X-ALD research since
1972, a drug therapy to lower the elevation of VLCFA as well
as to stop the neurological deterioration in X-ALD patients is
not yet available. Addition of monoenoic fatty acid (e.g. oleic
acid) to cultured skin ¢broblasts of X-ALD patients causes a
reduction of saturated VLCFA presumably by competition
for the same chain elongation enzyme. [10]. Treatment of X-
ALD patients with trioleate resulted in 50% reduction of
VLCFA. Subsequent treatment of X-ALD patients with a
mixture of trioleate and trieruciate (popularly known as Lo-
renzo’s oil) also led to a decrease in plasma levels of VLCFA
[10^12]. Unfortunately, the clinical e⁄cacy has been unsatis-
factory since no proof of favorable e¡ects has been observed
by attenuation of the myelinolytic in£ammation in X-ALD
patients [10]. Moreover, a recent study has demonstrated
that exogenous addition of unsaturated VLCFA induces the
production of superoxide, a highly reactive oxygen radical, by
human neutrophils [22]. Since cerebral demyelination of X-
ALD is associated with a large in¢ltration of phagocytic cells
to the site of the lesion [20], treatment with unsaturated fatty
acids may even be toxic to X-ALD patients.
Recently we have observed that lovastatin and NaPA in-
hibit the induction of nitric oxide synthase and proin£amma-
tory cytokines (TNF-K, IL-1L and IL-6) in rat primary astro-
cytes, microglia and macrophages [13] suggesting that these
drugs, alone or in combination, may represent a possible ave-
nue of research for therapeutics directed against cytokine- and
NO-mediated brain disorders, particularly in demyelinating
conditions. Lovastatin and NaPA have already been approved
for medication/drug trials for human diseases. Therefore, nor-
malization of VLCFA by lovastatin and NaPA in X-ALD
¢broblasts indicate that these drugs may be of therapeutic
value in lowering the levels of VLCFA and ameliorating the
myelinolytic in£ammation in X-ALD patients.
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